接受新型创新肾脏替代治疗的危重患者抗生素给药建议
该研究采用Monte Carlo模拟,基于已发表体重和药代动力学参数,预测头孢吡肟、头孢他啶、亚胺培南、美罗培南和哌拉西林/他唑巴坦在虚拟危重患者接受五种Tablo血液透析系统KRT方案时的药物暴露。以40-60%fT>MIC和40-60%fT>MICx4为标准疗效目标,评估目标达成概率(PTA)和毒性可能性,以1周治疗期间PTA≥90%的最小剂量为最优。结果显示KRT特征影响抗生素给药,可为所有KRT选项设计达到约90%PTA的β-内酰胺剂量,但头孢吡肟和哌拉西林/他唑巴坦的严格疗效目标方案可能超过毒性阈值。作者认为需进一步临床验证。
要点
- Tablo血液透析系统的流出率和治疗时长/频率组合可影响β-内酰胺类抗生素的清除,需个体化设计剂量。
- 以40-60%fT>MIC和40-60%fT>MICx4为疗效目标,Monte Carlo模拟可为五种KRT方案设计达到约90%PTA的β-内酰胺剂量。
- 头孢吡肟和哌拉西林/他唑巴坦方案若追求严格疗效目标,可能超过毒性阈值。
- 最优剂量定义为1周治疗期间PTA≥90%的最小剂量。
- 作者结论认为需进一步临床验证。
适用人群与场景
- 接受Tablo血液透析系统肾脏替代治疗的危重急性肾损伤患者(虚拟危重患者)。
诊断标准与关键阈值
- 疗效目标:标准游离β-内酰胺血浆浓度高于最低抑菌浓度的时间百分比40-60%fT>MIC和40-60%fT>MICx4。
- 最优剂量:1周治疗期间目标达成概率(PTA)≥90%的最小剂量。
研究设计与关键结果
- 研究类型:Monte Carlo模拟研究。
- 干预:预测头孢吡肟、头孢他啶、亚胺培南、美罗培南和哌拉西林/他唑巴坦在五种Tablo血液透析系统KRT方案下的药物暴露。
- 主要结果:Monte Carlo模拟确定了在所有KRT选项中达到约90%PTA的β-内酰胺剂量;KRT特征影响抗生素给药;头孢吡肟和哌拉西林/他唑巴坦为严格疗效目标设计的方案可能超过毒性阈值。
证据类型、等级与局限
- 证据类型:Monte Carlo模拟研究。
- 局限:原文报告需进一步临床验证。
对床旁实践的改变
- 作者认为,新型KRT系统提供的灵活性可影响β-内酰胺类抗生素给药,但可设计剂量以满足治疗目标。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The Tablo Hemodialysis System is a new innovative kidney replacement therapy (KRT) providing a range of options for critically ill patients with acute kidney injury. The use of various effluent rate and treatment durations/frequencies may clear antibiotics differently than traditional KRT. This Monte Carlo Simulation (MCS) study was to develop antibiotic doses likely to attain therapeutic targets for various KRT combinations.
METHODS: Published body weights and pharmacokinetic parameter estimates were used to predict drug exposure for cefepime, ceftazidime, imipenem, meropenem and piperacillin/tazobactam in virtual critically ill patients receiving five KRT regimens. Standard free β-lactam plasma concentration time above minimum inhibitory concentration targets (40-60%fT> MIC and 40-60%fT> MICx4) were used as efficacy targets. MCS assessed the probability of target attainment (PTA) and likelihood of toxicity for various antibiotic dosing strategies. The smallest doses attaining PTA ≥ 90% during 1-week of therapy were considered optimal.
RESULTS: MCS determined β-lactam doses achieving ∼90% PTA in all KRT options. KRT characteristics influenced antibiotic dosing. Cefepime and piperacillin/tazobactam regimens designed for rigorous efficacy targets were likely to exceed toxicity thresholds.
CONCLUSION: The flexibility offered by new KRT systems can influence β-lactam antibiotic dosing, but doses can be devised to meet therapeutic targets. Further clinical validations are warranted.
参考来源
- Lewis SJ, Mueller BA. Antibiotic dosing recommendations in critically ill patients receiving new innovative kidney replacement therapy. BMC Nephrol. 2024. PMID: 38413858. doi:10.1186/s12882-024-03469-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。